• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sutent (Pancreatic Cancer) - Analysis and Forecasts to 2020 - Product Image

Sutent (Pancreatic Cancer) - Analysis and Forecasts to 2020

  • Published: December 2011
  • 34 pages
  • GlobalData

Sutent (Pancreatic Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Sutent (Pancreatic Cancer) - Analysis and Forecasts to 2020” provides Sutent sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Pancreatic Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US and EU5
- Analysis and review of Sutent including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Pancreatic Cancer
2.2 Pancreatic Cancer Market
2.3 Epidemiology
2.4 Etiology
2.5 The Main Recognized Risk Factors
2.5.1 Cigarette Smoking
2.5.2 Age
2.5.3 Gender
2.5.4 Family History
2.5.5 Other Factors
2.5.6 Pancreatic Cancer Prevention
2.6 GlobalData Report Guidance
3 Pancreatic Cancer: Market Characterization
3.1 Pancreatic Cancer Disease Market
3.2 Pancreatic Cancer Disease Market Forecasts and CAGR
3.3 Drivers for the Pancreatic Cancer Disease Market
3.3.1 High Incidence
3.3.2 Large Unmet Need
3.3.3 Active Pipeline
4 Tumor-Node-Metastases (TNM) Classification of Pancreatic Cancer
4.1 Treatment Options in Pancreatic cancer
4.2 Classification of Patients with Pancreatic Cancer
5 Sutent
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Approval History of Sutent
5.5 Factors Affecting Sales of Sutent
5.5.1 Pancreatic Neuroendocrine (PNET) Tumor Market - A Niche Market
5.5.2 Sutent versus Conventional Treatment Options
5.5.3 Emergence of Targeted Therapies
5.5.4 Improving Diagnostic Techniques
5.6 Drug Evaluation
5.6.1 Drug Risk Benefit Score
5.6.2 Intensity of Competition
5.7 Sales Forecasts
5.7.1 Target Patient Pool of Sutent
5.7.2 Dosing
5.7.3 Market Penetration
5.7.4 Annual Cost of Therapy
5.7.5 Sales Projections of Sutent
6 Appendix
6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to Take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources

1.1 List of Tables
Table 1: Pancreatic cancer, Estimated Incidence and Mortality, 2008–2030
Table 2: Pancreatic Cancer, TNM Classification
Table 3: Approval History of Sutent
Table 4: Drug Risk Benefit Score of Sutent
Table 5: Sutent, Pancreatic Cancer, Global, Annual Cost of Therapy, 2011
Table 6: Sutent, Pancreatic Cancer, Global, Sales Forecasts ($m), 2010–2020
Table 7: Sutent, Pancreatic Cancer, The US, Sales Forecasts ($m), 2011–2020
Table 8: Sutent, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2010–2020
Table 9: Sutent, Pancreatic Cancer, France, Sales Forecasts ($m), 2010–2020
Table 10: Sutent, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2010–2020
Table 11: Sutent, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2010–2020
Table 12: Sutent, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2010–2020
Table 13: Sutent, Pancreatic Cancer, Japan, Sales Forecasts ($m), 2012–2020

1.2 List of Figures
Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2008
Figure 2: Total number of cigarettes consumed, The US, 1976-2006
Figure 3: Average Incidence Rate per 100,000, Pancreatic Cancer, the US, Both Sexes, 1992–2007
Figure 4: Incidence Rate per 100000, Pancreatic Cancer, the US, Both Sexes, 2010–2030
Figure 5: Pancreatic Cancer, Global, Market Size Forecasts ($m), 2010–2020
Figure 6: Pancreatic Cancer, Worldwide, Incidence (in million), 2008-2030
Figure 7: Oncology, Worldwide, Incidence (in million), 2008-2030
Figure 8: Broad Classification of Pancreatic Cancer
Figure 9: Classification of Patients with Pancreatic Cancer
Figure 10: Drug Model Diagram of Sutent
Figure 11: Sutent, Pancreatic Cancer, Global, Sales Forecasts ($m), 2010–2020
Figure 12: Sutent, Pancreatic Cancer, The US, Sales Forecasts ($m), 2011–2020
Figure 13: Sutent, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2010–2020
Figure 14: Sutent, Pancreatic Cancer, France, Sales Forecasts ($m), 2010–2020
Figure 15: Germany Pancreatic Cancer, Germany, Sales Forecasts ($m), 2010–2020
Figure 16: Sutent, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2010–2020
Figure 17: Sutent, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2010–2020
Figure 18: Sutent, Pancreatic Cancer, Japan, Sales Forecasts ($m), 2012–2020
Figure 19: Sutent, Pancreatic Cancer, Global, Sales Distribution (%), 2020
Figure 20: Patients Approved for the Drug

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos